Comparative Pharmacology
Head-to-head clinical analysis: SEMPREX D versus TAVIST 1.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SEMPREX D versus TAVIST 1.
SEMPREX-D vs TAVIST-1
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
SEMPREX-D combines acrivastine, a histamine H1 receptor antagonist, and pseudoephedrine, a sympathomimetic amine vasoconstrictor. Acrivastine blocks peripheral histamine-mediated effects, while pseudoephedrine constricts nasal blood vessels to reduce congestion.
TAVIST-1 (clemastine fumarate) is a first-generation antihistamine that acts as a competitive antagonist at histamine H1 receptors, thereby preventing histamine-mediated effects such as vasodilation, increased capillary permeability, and bronchoconstriction. It also exhibits anticholinergic and sedative properties.
1 capsule orally every 12 hours; each capsule contains acrivastine 8 mg and pseudoephedrine 60 mg.
1.34 mg orally twice daily; maximum 8.04 mg/day.
None Documented
None Documented
Terminal elimination half-life is approximately 8-12 hours, allowing twice-daily dosing.
Terminal half-life 12–15 hours; clinical dosing interval every 12 hours.
Renal (approx. 60% as unchanged drug and metabolites), biliary/fecal (approx. 40%).
Primarily renal: ~60% unchanged; biliary/fecal: ~30% as metabolites; minor via feces.
Category C
Category C
Antihistamine/Decongestant Combination
Antihistamine